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Different batches of atorvastatin, represented by two immediate release formulation designs, were studied using a novel dynamic
dissolution apparatus, simulating stomach and small intestine. A universal dissolution method was employed which simulated
the physiology of human gastrointestinal tract, including the precise chyme transit behavior and biorelevant conditions. The
multicompartmental dissolution data allowed direct observation and qualitative discrimination of the differences resulting from
highly pH dependent dissolution behavior of the tested batches. Further evaluation of results was performed using IVIVC/IVIVR
development. While satisfactory correlation could not be achieved using a conventional deconvolution based-model, promising
results were obtained through the use of a nonconventional approach exploiting the complex compartmental dissolution data.
1. Introduction
An orally administered drug has to be released from its
dosage form, dissolved in the surrounding fluid and absorbed
by the gutwall, in order to enter the blood stream.Dissolution
testing in pharmacy studies the first two processes and is not
only a vital tool for assessment of quality of a pharmaceutical,
but also a tool for elucidation and simulation of these effects
in vitro. The research in drug development facilitates dissolu-
tion to uncover and predict many crucial aspects influencing
the fate of an administered active pharmaceutical ingredient
(API) in the gastrointestinal tract (GIT), while employing
a wide variety of innovative and special apparatuses, either
based on the conventional pharmacopeial tools or having
a completely original design [1]. Such instruments usually
involve only one or two compartments, and they functionally
often address only a specific focus of a study, that is, drug
precipitation, mechanical qualities of a dosage form, and so
forth [2]. However, a more complex simulation of the GIT
is often needed, and currently only TIM-1 apparatus fully
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Figure 1: Front view with description of main components: (1) stomach, (2) duodenum, (3) jejunum, (4) ileum, (5) collection canister tubing,
(6) pH probes, and (7) peristaltic pumps.
enables in vitro testing in completely biorelevant conditions
ranging from stomach to ileum [3].
In order to provide other means of highly biorelevant and
dynamic dissolution testing, our team has developed a novel
four-compartmental dissolution apparatus, named “Golem,”
which simulates the dissolution processes in stomach and
small intestine (SI). This paper discusses the application and
evaluation of this apparatus, performed with several generic
and reference batches of immediate release tablets containing
atorvastatin (ATV). This drug was chosen due to the avail-
ability of in vivo data from subsequent bioequivalence (BE)
studies for the tested formulations.
ATV is characterized by low solubility in water and
high permeability and is hence classified as a Class II drug
in the Biopharmaceutical Classification System (BCS) [4].
Dissolution is the rate-limiting step in absorption of ATV,
and IVIVC could be expected according to the BCS theory.
But being a drug of limited bioavailability, due to high
variability in first-pass metabolism, makes it difficult to
correlate the conventional in vitro tests results with blood
concentration in time (or other pharmacokinetic parame-
ters).Therefore an attempt to establish an in vitro-in vivo cor-
relation/relationship model for this drug was made, based on
the dissolution data obtained from this novel unconventional
dissolution instrument.
2. Materials and Methods
2.1. Golem Apparatus. The instrument is a computer con-
trolled artificial digestive tract, designed for dynamic disso-
lution testing of oral dosage forms and consisting of four
compartments: stomach, duodenum, jejunum, and ileum
(see Figure 1). Physiological conditions are maintained in the
system with the possibility of adjusting all method param-
eters, for example, pH, volumes, transit times, temperature,
and so forth. The dissolution in fed state can be tested
with liquid meal (e.g., Nutridrink, Ensure Plus, or very
finely homogenized solid meal to prevent clogging of the
pump tubes). The transport of chyme in Golem is driven
by peristaltic pumps placed between each two subsequent
compartments, where the fourth pump leads the chyme from
the ileum into the collection canister (waste). The pH in the
compartments is checked automatically by pH probes and is
manually adjusted by injection of either 1M NaOH + 0.24M
NaHCO
3
or 1M HCl solution.
The compartments are made from modified common
intravenous bags (the plastic was tested for interaction with
various APIs). The bags involve three ports: one holds plastic
tubes for injection of pH altering solutions, enzymes, and
sample collection; second port serves as a mouthpiece for
the pH probe, and the third port is used for tablet insertion
into the compartments. Temperature is kept at physiological
37∘C and continuously checked separately for: (a) the heater
platform; (b) the stomach compartment; (c) the air inside
the apparatus box. Peristaltic movement is simulated by a V-
shaped grate, pressed down on the bags, which rocks from
side to side, driven by compressed air.
The operation of the apparatus requires one person for
manual collection of samples and injection of enzymes, using
common syringes.
From perspective of biorelevancy, the Golem apparatus
is one of the three most complex dissolution apparatuses
described to date (other two being TIM-1 and Dynamic
Gastric Model) [3]. Its main advantage is that the complex
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Table 1: Dissolution method description.
Stomach Duodenum Jejunum Ileum
Starting volume (mL) 30 (gastric juice) + 200 (deionized water) 33 33 33
Residence/transit time (min) 30; linear emptying 10 60 90
pH 2.4 (at 37∘C) 6.5 6.6 7.4
Pepsin (mg/mL) 1.3 — — —
Lipase activity (U/mL) — 70 70 70
Bile salts (mM) — 3 3 3
functions are based on simple technical solutionswhichmake
the apparatus user friendly and easy to modify, and at the
same time significantly less expensive than the alternatives.
The instrument was designed by Rˇeza´cˇova´, Dohnal,
Jampı´lek and Cˇulen, and constructed by DevelopmentWork-
shops of the Institute ofOrganic Chemistry andBiochemistry
of the Czech Academy of Sciences [5].
2.2. Dissolution Method. A method simulating fasted state
and developed according to previous work was used in the
study [6].
Prior to the dissolution experiments, the contents of the
compartments were heated to 37∘C. The experiments were
started directly after insertion of a dosage form into the first
stomach compartment. The gastric medium containing both
the dissolved and undissolved contents of the dosage form
was gradually moved by the peristaltic pump from stomach
into the duodenal compartment and then into the follow-
ing two compartments (an approximate scheme of chyme
transfer in Golem is depicted in Figure 2). The medium thus
underwent a dynamic change as it merged with the contents
(starting volumes) of the next compartments. The starting
dissolution medium was based on a physiological solution
with pHmodified by hydrochloric acid or bicarbonate buffer;
pepsin was added only to the gastric compartment. The pH
values, concentration of bile salts (bile extract porcine, Sigma-
Aldrich), and lipase (pancreatin, Zentiva) in the SI compart-
ments weremaintained at steady levels throughout the exper-
iment. The pH in stomach compartment was left to change,
being influenced by the studied formulation. The detailed
information on the method design is given in Table 1.
All experiments were performed in duplicates.
2.3. Sample Analysis. The samples were collected manualy
using common syringe; 1mL of sample was filtered through
a 0.25 𝜇m syringe filter, and the rest was returned into the
apparatus. The withdrawal of the medium and dissolved API
was considered in the calculations. The filtered sample was
analyzed with HPLC (Waters) at 𝜆 = 246 nm.
2.4. Formulations Tested. In total, five generic (Zentiva) and
three reference originator immediate release tablet batches
were tested with Golem, all containing 80mg of atorvastatin,
present as a calcium salt. From the generic batches, four
contained amorphous form of the drug (batches 85, 82, 01,
and 02), which had higher intrinsic dissolution rate compared
with the crystal form contained in the generic batch80 and
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Figure 2: An approximated visual scheme of chyme transit in the
Golem apparatus. A residual volume equal to the starting volume
remained in each compartment, therefore the “total” amountmoved
through the apparatus was 200mL.
all the reference batches (Lipitor, Sortis06, Sortis10) [10]. All
formulations with the crystal ATV also containedCaCO
3
as a
buffering agent used to raise the gastric pH and thus facilitate
very early dissolution of ATV, which is a weak acid almost
insoluble in pH below 4. The amorphous generic batches, on
the other hand, contained no buffer, which was to slow down
the faster dissolution of the amorphous form of the drug.
2.5. Pharmacokinetic (PK) Studies. The BE studies of the five
generic formulations were evaluated in four crossover PK
studies, performed by other contract workplaces: (a) Batch85
versus Sortis03, 24 subjects; (b) batches 01 and 02 versus
Sortis03, 24 subjects; (c) batch82 versus Sortis10, 102 subjects;
(d) batch80 versus Lipitor, 81 subjects.
2.6. Modeling. In order to establish a relationship between
dissolution test results and actual results from in vivo studies,
different modeling approaches were applied.
2.6.1. Classical Approach. A conventional method was based
on a numeric deconvolution, where whole in vitro profiles
of cumulative fraction dissolved were taken into account,
with or without exclusion of the measurements from selected
compartments.The𝑅 statistical computing softwarewas used
for modeling. An Rivivc package [11] and self-written 𝑅
scripts were used to preprocess data and perform numerical
deconvolution. In order to calculate fraction of drug absorbed
in time, simulated in vivo profile (i.v. administration) was
used as an equivalent to the unit impulse response (UIR).
4 BioMed Research International
Table 2: Intravenous administration simulation parameters.
Parameter group Parameter Value Source
Physicochemical and binding
Mol. weight (g/mol) 558.6 [http://www.drugbank.ca/]
log𝑃 5.7 [http://www.drugbank.ca/]
Compound type Monoprotic Acid [http://www.drugbank.ca/]
pKa 1 4.330 [http://www.drugbank.ca/]
B/P 0.610 [7]
Fu 0.107 [8]
ADME
Enzymatic clearance
Pathway p-Hydroxy o-Hydroxy p-Hydroxy
Enzyme CYP3A4 CYP3A4 CYP2C8
𝑉max 29.800 29.300 0.290 [9]
𝐾
𝑚
25.600 29.700 35.900
fu mic 0.662 0.662 0.662
Total plasma clearance-CL (Hep) 26.93 L/h [Fitted to the clinical data]
log𝑃—logarithm of the octanol-water partition coefficient; pKa—dissociation constant; B/P—blood-to-plasma partition coefficient; fu—fraction unbound in
plasma; 𝑉max—maximum reaction rate achieved by the system;𝐾𝑚—substrate concentration at which the reaction rate is half of 𝑉max.
Simulation of in vivo profile after i.v. administration was car-
ried out on Simcyp Population-based Simulator V13R1 and
was based on the results for ten virtual healthy patients [12].
Minimal PBPK model with single adjusting compartment
(SAC) was utilized. Volume of distribution was calculated
with use of the model based upon a modified version of
the Poulin andTheil method [13]. Input information covered
system data specific for the chosen population (as provided
by simulator), trial design information (single 30 seconds
long i.v. bolus, 80mg), and compound specific data. Physic-
ochemical, binding, and ADME (absorption, distribution,
metabolism, and excretion) data are presented in Table 2.
Renal clearance of ATV was assumed to be negligible
[14].
2.6.2. Compartmental Approach. A second approach was
based on direct scaling of the outcome of tests carried
on Golem apparatus, where particular compartments were
correlated with in vivo profiles.
2.7. Model’s Predictability Evaluation. A proper IVIVCmodel
should be established using formulations with different
release rates. At minimum three (slow, medium, and fast
dissolving) dosage forms should be designed, where the
extreme ones are used to build a model able to predict in
vivo bioperformance of the “middle” formulation. Such an
approach is common when sustained-release dosage forms
are tested but becomes problematic with immediate-release
formulations (IR). All batches of the model drug, atorvas-
tatin, were of immediate release and in the case of either
the buffered or the nonbuffered formulations were behaving
similarly. Therefore, external predictability and validation
were evaluated when one formulation was characterized by
medium rate release kinetics, used as testing formulation, and
two other formulations were used for model building. In case
of internal validation, testing formulation was included in
model building phase. Whole or partial area under the curve
(pAUC) prediction error (PE) (1) and 𝐶max prediction error
(2) was calculated [15]:
pAUC PE [%] = [
󵄨󵄨󵄨󵄨󵄨
pAUCobserved − pAUCpredicted
󵄨󵄨󵄨󵄨󵄨
pAUCobserved
] ∗ 100,
(1)
𝐶max PE [%] = [
󵄨󵄨󵄨󵄨󵄨
𝐶max,observed − 𝐶max,predicted
󵄨󵄨󵄨󵄨󵄨
𝐶max,observed
] ∗ 100. (2)
3. Results and Discussion
3.1. PK Studies. Bioavailability of the five generic batches
was compared with three batches of the reference product
(atorvastatin 80mg manufactured by Pfizer, under the brand
names Lipitor and Sortis, sold on different markets), in total
of four consecutive PK studies. The PK data served as a
qualitative “ladder” for the dissolution experiments and as
basis for IVIV correlations.
Theparticular BE study results were as follows: (a) generic
batch85 compared with Sortis03 showed 𝐶max below the
approved range for bioavailability (90% confidence interval
(CI) ratio of 75%); (b) both batches 01 and 02 later showed
much higher 𝐶max than the reference Sortis03 (90% CI ratio
160 and 140%, resp.); (c) the batch82 was bioequivalent
to Sortis10; (d) the much later developed batch80 (first
generic batch with crystal API) has shown slightly higher
but unacceptable bioavailability, with upper 90% CI of 127%.
The average plasma concentration-time profiles are plotted
together in Figure 3.
In general, the drug’s pharmacokinetics showed a consid-
erable interindividual variability, which is well reflected in the
average PK profiles (see Figure 2).Themost important origin
of the variability seems to be the gut and liver metabolism
of the drug [16]. An important observation from the average
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Figure 3: Bioequivalence studies results. Sortis03 was tested twice,
in two PK studies.
PK curves is the very short 𝑇max values (0.67–1.00 h), which
suggested a very rapid dissolution and absorption in GIT.
3.2. Dissolution Results. The Golem dissolution experiments
were started with batch80 and its reference product Lipitor,
since both products contained the same crystal form of
ATV, and both were buffered by CaCO
3
, as excipient. The
two formulations were run with the full-length fasted state
dissolution method, lasting 215min. Figure 4 shows the dis-
solution results as concentration or fraction of drug dissolved
for all four Golem’s compartments separately and also in a
cumulative profile. Both formulations showed almost parallel
dissolution profiles, but with higher dissolved amount in case
of batch80, which qualitatively corresponded with the in vivo
results. Generally, the tablets were observed to disintegrate
in the first 3min; the API quickly dissolved and the slight
increase in the cumulative dissolved amount of API after
100min could be mainly accounted for the higher pH in
ileum.The fact that the fraction dissolved did not surpass 45%
wasmost probably caused by the salting out effect of the Ca2+
counter-ion coming from the buffering excipient.
Since the maximum plasma concentrations in vivo were
reached between 40 and 60min and the dissolution profiles of
the IR tablets provided little information at later time points,
all further dissolution tests with the remaining batches were
decided to be run with the same fasted state method but
terminated directly after the sampling point at 43min.
The further tested buffered formulations included two
reference batches from the BE studies (Lipitor and Sortis10),
plus one other batch of the reference product, Sortis06. All
three reference batches showed almost identical dissolution
behavior (see Figure 5), which confirmed that they were
interchangeable in the dissolution experiments.
The dissolution testing of nonbuffered generic formula-
tions revealed that no API dissolved in the stomach compart-
ment, although the tablets disintegrated completely in less
than 3min. In contrast, all buffered formulations, generic and
reference alike, raised the gastric pH to 7-8, which enabled
rapid dissolution of ATV. The results came as a surprise
in comparison with traditional USP II tests, which were
performed with 900mL of simple buffered media, where
the pH was raised by the buffered formulations only to
values around 4, thus prohibiting discrimination between the
two formulation designs (unpublished results).This observed
difference between the buffered and nonbuffered formulation
in Golem provided a useful hint on the manner of in vivo
dissolution behavior.
As for the nonbuffered batches, these generally provided
higher fraction dissolved as they did not contain the CaCO
3
buffering agent. Other than that, the batch85 with low
bioavailability in vivo had the lowest dissolution perfor-
mance, followed by the bioequivalent batch82, and then
the two batches with highest bioavailability—batch01 and
batch02. However, the dissolution profiles for batches 01 and
02 were identical, and, according to similarity and difference
factor, they also did not differ from the profile of batch82.
Moreover, API powder which served as a control also showed
identical dissolution performance to batches 01 and 02,
indicating that the dissolution method lacked discriminatory
power for these highly dissolving batches. This was caused
by low medium volume (although physiological) in com-
bination with lack of an absorption step (sink-condition).
Nevertheless, the dissolution method was developed as a
universal, most physiologically relevant simulation of fasted
state, and as such it provided results beyond expectation.The
obvious and simple option for improvement of dissolution
testing of drugs with low solubility (such as atorvastatin)
would be modification of the method by employing higher
(unphysiological) medium volumes in the individual com-
partments, which would prevent early saturation of medium
with the tested API. Of course, certain very lipophilic drugs
would require unachievably high medium volumes to enable
full dissolution of the administered dose. It is however
questionable whether this is necessary when considering
the fact that such drugs would neither be expected to fully
dissolve in vivo. However, study of these effects was beyond
the scope of the present study.
3.3. IVIVC-Classical Approach. The results depicted below
follow a general agenda of in vitro-in vivo correlation level
A, where fraction absorbed in vivo is directly correlated to
the fraction dissolved in vitro. A linear function is preferred
for this correlation, although other reasonable mathematical
relationships are allowed when properly justified. The key
procedure here was a deconvolution of a PK profile into the
cumulative curve describing fraction absorbed in vivo. Since
atorvastatin PK p.o. profile does not follow 1-compartment
nor even 2-compartment model, classical Wagner-Nelson or
Loo-Riegelman deconvolution methods could not be applied
here. Instead, more sophisticated numerical deconvolution
was employed. Numerical deconvolution relies on the avail-
ability of a PK profile of drug administered intravenously
(i.v.), thus representing pure distribution/elimination phase,
without absorption. Since in the presented case, bioassay
protocol did not include such atorvastatin administration, an
approximation of i.v. profile by computer simulations, carried
out with Simcyp software, was used.
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Figure 4: Golem dissolution results for nonbuffered generic batch80 and its reference product Lipitor. The plots show dissolution behavior
measured in separate compartments, as well as cumulative profile showing the amount of drug dissolved in the whole apparatus including the
amount gradually transferred from ileum into the collection canister.The terminal decrease of dissolved amount in individual compartments
was caused by transfer of portions of the medium into the following compartment, or into the collection canister in case of ileum.
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In case of the dissolution results available, the presence
or absence of the buffering agent affected whether drug
did dissolve in the stomach compartment, which produced
two distinct cumulative profile patterns and significantly
limited the comparison of the two formulation designs. In
vivo absorption of atorvastatin is believed to start only in
small intestine and thus a deconvolution of plasmatic profile
would yield a fraction of drug absorbed only from small
intestine. According to this, the fraction of drug dissolved
in stomach compartment was excluded from the cumulative
profiles used for the IVIV correlations.The final profiles used
for correlation are depicted in Figure 6.
Despite the previous modification of the profiles, the
lower solubility of ATV in the presence of CaCO
3
and
the resulting overall lower dissolution performance of the
buffered batches caused that it was difficult to build a reli-
able model using combination of buffered and nonbuffered
formulations. Therefore, models had to be built for Design
I (buffered batches) and Design II (nonbuffered) separately.
Figure 7 depicts deconvolution results for two formulations
of both designs and the lack satisfactory level of correlation
(𝑅2 = 0.37). Deconvolution was performed using simulated
in vivo response after intravenous administration of 80mg of
ATV (Figure 8).
In vitro-in vivo correlation was described by both linear
and nonlinear (polynomial) relationship (3). Thelm() 𝑅
base function was used:
FABS = 𝐵
0
+ 𝐵
1
∗ FDISS + 𝐵
2
∗ FDISS2 + 𝐸, (3)
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Figure 6: Cumulative fraction of ATV dissolved in duodenum,
jejunum, and ileum compartments.
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Figure 7: IVIVC plot for batches tested in two different conditions.
where FABS is the fraction absorbed, 𝐵
0
is the 𝑦-intercept, 𝐵
1
and 𝐵
2
are coefficients, FDISS is the fraction dissolved, and 𝐸
are residuals.
3.3.1. Design I. In the nonbuffered group a model was built
based on batch01 and batch85 and nonlinear (polynomial)
correlation was obtained with 𝑅2 = 0.951 (Figure 9).
Predictability evaluation was performed by calculating
fraction of ATV absorbed versus time with regression equa-
tion with in vitro profile as an input. With intravenous
response profile, numerical convolution was performed, and
the prediction of in vivo curve was obtained. Figure 10 depicts
simulation of in vivo profile of batch82.
The model’s prediction errors for 𝐶max and AUC did not
meet the FDA criteria [15] and were to be rejected.
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3.3.2. Design II. Deconvolution results for buffered batches
are presented in Figures 11 and 12. In most cases, nonlinear
correlation was observed.
In Figure 13, prediction of Sortis10 plasma concentration
is shown. Although AUC PE was low (5.75%), the prediction
of 𝐶max was not satisfactory.
An example of internal predictability is presented in
Figure 14. In general, predictions of 𝐶max were good, but
the descending curves could not properly reflect the in vivo
behavior resulting in high AUC PE. This was partially due to
the fact that the simulated i.v. profile used for deconvolution
(and later convolution in the validation phase) was the same
for all batches and not fitted to each group of patients
participating in clinical trials.
3.4. IVIVC/IVIVR-Compartmental Approach. In order to
fully exploit Golem’s features, it was attempted to cre-
ate IVIVR introducing completely nonstandard approaches,
where no conventional convolution/deconvolution methods
are necessary. This implies no more requirements for i.v.
administration results, and therefore results obtained in
a more cost-saving manner, utilizing the Golem data for
IVIVC/IVIVR development.
TheGolem apparatus allowsmeasuring the concentration
of API in each compartment separately. An example of dis-
tribution of dissolved API for Lipitor is depicted in Figure 15.
Various approaches were examined to correlate results
for each compartment with corresponding in vivo profiles,
but successful outcome was reached only with jejunum
compartment. As shown in Figure 16, profiles were described
by nonlinear function:
𝑓 (𝑡) = 𝐴 ∗ 𝑒
(−𝑘1∗𝑡)
+ 𝐵 ∗ 𝑒
(−𝑘2∗𝑡)
+ 𝐶 ∗ 𝑒
(−𝑘3∗𝑡)
, (4)
where 𝑓(𝑡) is the concentration of an API at given sampling
time 𝑡; 𝐴, 𝐵, and 𝐶 are the equation constants; 𝑘1, 𝑘2, and 𝑘3
are constants.
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Figure 9: Deconvolution results for nonbuffered batch02 and
batch85.
Themodel presented above follows a general equation for
2-compartment model with p.o. administration, and despite
the previously mentioned claim that ATV PK profile does
not follow such model well, it was chosen as a compromise
between modeling accuracy and optimization procedure
stability.
Formula was optimized with nonlinear Solver (DEPS:
differential evolution and particle swarm optimization) avail-
able in LibreOffice Calc (ver. 4.1.5.3). Figure 16 represents
measurements for jejunum compartment for each batch
(Figure 16(a)). A complete measurement was available only
for Lipitor and batch80, and the descending part of the in vitro
curves for the six remaining batches had to be introduced
by addition of two time points (Figure 16(b)) in order to
perform in vivo time scaling and correlation. Correlation of
full profiles was performed for Lipitor and batch80 and was
used for internal validation of the model. Only the ascending
(and in vitro measured) parts of profiles were correlated for
the remaining batches.
As shown in Figure 17, in vivo time scale was scaled
nonlinearly, however with a simple reversible mathematical
function.
Finally, with (5), predicted plasma concentrations were
calculated for all batches. Two constants were introduced for
linear scaling of in vitro profile and were optimized with
nonlinear Solver:
𝑓 (𝑡) = CONST1 ∗ [𝐴 ∗ 𝑒(−𝑘1∗𝑡) + 𝐵 ∗ 𝑒(−𝑘2∗𝑡) + 𝐶 ∗ 𝑒(−𝑘3∗𝑡)]
+ CONST2,
(5)
where 𝑓(𝑡) is the predicted plasma concentration at given
time 𝑡; 𝐴, 𝐵, 𝐶, 𝑘1, 𝑘2, and 𝑘3 are constants calculated
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Figure 10: Prediction of in vivo profile of batch82 with nonlinear model built on batch02 and batch85.
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Figure 11: Nonlinear IVIVC example.
for in vitro jejunum profile (4); CONST1 and CONST2 are
constants for whole in vitromodel linear scaling.
For CONST1 and CONST2 optimization, only two
formulations were used and a middle one (with medium
dissolution rate) was predicted.
3.4.1. Designs I and II. Results for external prediction of
batch01 (amorphous ATV, nonbuffered) PK profile are pre-
sented in Figure 18. Although constants for in vitro profile
scaling were optimized for batch80 and Lipitor (buffered
conditions), pAUC PE and 𝐶max PE for batch01 were below
10%.
3.4.2. Design II. Model was optimized for batch80 and
Lipitor, since these were the two most extensively studied
batches (215min in vitro profiles), and their in vivo profiles
sufficiently differed between each other (Figure 19).
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Figure 12: Linear IVIVC example.
In Figure 20, the prediction for Sortis06 is shown. Pre-
diction errors were below 20%, which means that according
to FDA guidance [15] the model is not to be rejected, but
additional data should be provided in order to be fully
validated.
In summary, the compartmental approach directly corre-
lated the in vitro jejunal dissolution profile with the course
of the plasmatic versus time profile. The logical basis for this
correlation was the assumption that any dissolved portion
of API in vivo would be immediately absorbed due to the
nonlimiting permeability of ATV, which allows direct corre-
lation of the ascending part of the dissolution and plasmatic
profiles. This approach provided the best correlation options
even for the combination of both formulation designs. This
could be accounted for the fact that each compartment
of the SI contained additional 33mL of starting volume,
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Figure 13: Prediction of Sortis10 profile.
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Figure 15: Example of measurements performed with Golem
apparatus (for Lipitor).
and this portion of fresh medium in the jejunum provided
sufficient sink-condition to allow dissolution of API without
saturation of the solution during the early minutes in this
compartment. The differences between the batches were
thus more pronounced here than elsewhere in the appara-
tus.
From the correlation-development view, however, the
basis for direct correlation was purely empirical. The
approachwith directmapping of jejunumprofileswith the PK
profiles was based on the observation of profound similarity
of both types of the results. Regardless of any mechanistic
considerations presented above, the most appealing point
here was to discard complicated convolution/deconvolution
methods in favor of simple linear or nonlinear mapping of in
vitro to the in vivo profiles. Thus, intravenous administration
of the API was no longer necessary here, and mathematical
limitations of convolution/deconvolution techniques were
not anymore applicable. It should be, however, pointed out
that in order to achieve such a relatively simple mathematical
model, it is necessary to provide physiologically relevant
dissolution results. In theory, this can be regarded as an
inverse proportion between the sophistication of numerical
procedures necessary for IVIVC/IVIVR and the degree of
faithful representation of biological processes by the dissolu-
tionmethod.Therefore, the presentedmodels demonstrating
very good correlation could serve as an indirect proof of the
Golem’s biorelevance. Moreover, in the future, the Golem’s
flexibility could allow defining its critical operational param-
eters that could be optimized in order to achieve itsmaximum
biorelevance in regard to the individual formulations tested.
An apparatus like Golem can utilize dissolution method
easily tailored to a particular formulation or API, based on
the quantitative and qualitative composition, knowledge on
the API’s physicochemical and biopharmaceutical character-
istics and other factors. An individual formulation-related
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Figure 16: Dissolution in jejunum compartment (a) and addition of two additional time points (b).
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Figure 18: Prediction of batch01 profile with model built on batch80 and Lipitor.
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Figure 20: Prediction of Sortis06 profile with model built on batch80 and Lipitor.
dissolution protocol could thus be an answer to the industrial
need for discriminative and at the same time biorelevant dis-
solutionmethods, whereas standardization could be achieved
on the level of algorithmic approach to the adjustment of the
dissolution protocol.
4. Conclusions
Dissolution of eight IR batches of ATV was tested using a
novel dissolution apparatus allowing dynamic simulation of
stomach and small intestine. The biorelevant conditions and
observation of succeeding dissolution processes in separate
compartments provided comprehensive information on the
dissolution behavior expected in vivo. Such information and
elucidation of the connections between processes happening
under different conditions, which are however connected in
vivo, are often inaccessible with the use of less complex appa-
ratuses. The dissolution testing was performed with a basic
universal dissolution method based on a faithful simulation
of theGI tract. As such, it defined themain effects influencing
dissolution performance of the tested batches, which is an
important and often difficult step in research and develop-
ment (R&D) and is a basic prerequisite for further dissolution
method optimization, performed according to the character-
istics of the givenAPI and its formulation.Due to the complex
nature of the presented apparatus, any modification of the
dissolution method can be easily performed. In case of the
correlation options, the structure ofGolem apparatus allowed
treating different compartments separately, adding or sub-
tracting the measurement results for each compartment. As
a result, two approaches to in vitro-in vivo correlation could
be developed. The main advantage of the presented methods
was no requirement for additional intravenous drug admin-
istration (simulated data for i.v. administration was used in
first approach) which might be inaccessible in certain cases.
Whole analysis with deconvolution was performed in a single
𝑅 script and therefore results are completely reproducible.
Compartmental approach can be redone in a spreadsheet and
standardized according to the industrial requirements, thus
presenting simple and effective tool for quick establishment
of IVIVC/IVIVR based on Golem’s results.
In order to fully evaluate the Golem’s capabilities and the
presented correlation techniques, larger dataset with greater
differences in dissolution rates should be used.
The future work with the apparatus will be aimed at gene-
rating and processing of further larger datasets for further
verification of the hypotheses presented in this paper.
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